KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Palvella Therapeutics (PVLA) Equity Ratio (2016 - 2026)

Palvella Therapeutics has reported Equity Ratio over the past 10 years, most recently at 0.98 for Q4 2022.

  • Quarterly Equity Ratio fell 397.12% to 0.98 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was 0.98 through Dec 2022, down 397.12% year-over-year, with the annual reading at 0.98 for FY2022, 397.12% down from the prior year.
  • Equity Ratio was 0.98 for Q4 2022 at Palvella Therapeutics, down from 0.39 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.4 in Q1 2020 and troughed at 0.98 in Q4 2022.
  • The 5-year median for Equity Ratio is 0.33 (2021), against an average of 0.25.
  • Year-over-year, Equity Ratio skyrocketed 618.79% in 2018 and then tumbled 397.12% in 2022.
  • A 5-year view of Equity Ratio shows it stood at 0.28 in 2018, then increased by 28.81% to 0.36 in 2019, then decreased by 18.82% to 0.3 in 2020, then grew by 11.86% to 0.33 in 2021, then tumbled by 397.12% to 0.98 in 2022.
  • Per Business Quant, the three most recent readings for PVLA's Equity Ratio are 0.98 (Q4 2022), 0.39 (Q2 2022), and 0.39 (Q1 2022).